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Abstract
Background: Anemia is associated with poor prognosis in heart failure (HF) patients. Contributors to the risk of anemia in
HF include hemodilution, renal dysfunction and inflammation. Hemoglobin levels may also be negatively affected by
alterations in stress regulatory systems. Therefore, psychological distress characterized by such alterations may adversely
affect hemoglobin in HF. The association between hemoglobin and Type D personality and affective symptomatology in the
context of HF is poorly understood.
Aim: To examine the relationship between Type D personality and affective symptomatology with hemoglobin levels at
inclusion and 12-month follow-up, controlling for relevant clinical factors.
Methods: Plasma levels of hemoglobin and creatinine were assessed in 264 HF patients at inclusion and at 12-month follow-
up. Type D personality and affective symptomatology were assessed at inclusion.
Results: At inclusion, hemoglobin levels were similar for Type D and non-Type D HF patients (p = .23), and were moderately
associated with affective symptomatology (r = –.14, p = .02). Multivariable regression showed that Type D personality (b = –
.15; p = .02), was independently associated with future hemoglobin levels, while controlling for renal dysfunction, gender,
NYHA class, time since diagnosis, BMI, the use of angiotensin-related medication, and levels of affective symptomatology.
Change in renal function was associated with Type D personality (b = .20) and hemoglobin at 12 months (b = –.25). Sobel
mediation analysis showed significant partial mediation of the Type D – hemoglobin association by renal function
deterioration (p = .01). Anemia prevalence increased over time, especially in Type D patients. Female gender, poorer
baseline renal function, deterioration of renal function and a longer HF history predicted the observed increase in anemia
prevalence over time, while higher baseline hemoglobin was protective.
Conclusion: Type D personality, but not affective symptomatology, was associated with reduced future hemoglobin levels,
independent of clinical factors. The relation between Type D personality and future hemoglobin levels was mediated by
renal function deterioration.
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Introduction
Anemia is a common comorbidity in chronic heart failure (HF).
In patients with comorbid kidney disease, more severe HF
symptoms and in older patients, the prevalence of anemia ranges
from 30 to 61%. In ambulatory HF patients with less severe HF
symptoms (e.g. NYHA class I & II) the prevalence of anemia
ranges from 4 to 23% [1]. Anemia is associated with symptoms of
HF, such as dizziness, tachycardia, and dyspnea [2], as well as
more frequent hospitalization [3], reduced health-related quality
of life [4], and increased risk of mortality [5,6]. The prevalence of
anemia is closely related to the level of New York Heart
Association (NYHA) functional class involved [7], indicating that
anemia becomes more prevalent when HF becomes more severe
and more symptomatic. The incidence and severity of anemia has
also been associated with the progression of chronic renal
dysfunction, another common comorbidity in HF [8].
In the majority of cases, anemia develops in HF patients as a
result of their chronic disease [1]. Anemia in HF may have
multiple origins, which are thought to involve reduced erythrocyte
production, decreased body mass index (BMI) and hemodilution
[1]. Further contributors to the risk of anemia in HF are comorbid
renal disease and increased inflammation. Renal dysfunction may
lead to a decrease in erythropoietin levels, and a subsequent
decrease in bone marrow erythrocyte production [9]. Elevated
levels of pro-inflammatory cytokines may also inhibit hematopoi-
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etic proliferation [10] which, in turn, causes anemia [9], also in
patients with HF [11]. Another potent factor in the development
of anemia (or pseudo-anemia) is hemodilution, due to increased
plasma volume [12]. Finally, medication affecting the renin-
angiotensin system (i.e. ACE inhibitors and angiotensin receptor
blockers) reduces erythropoietin production and lowers hemoglo-
bin levels [1].
In addition to these physiological mechanisms, animal research
shows that psychological stress may also promote anemia. In
rodents, acute psychological stress induced a decrease in blood and
bone marrow iron and inhibited erythropoiesis [13,14], while
chronic psychological stress was associated with even lower plasma
iron levels [14]. In humans, there is also a link between anemia
and psychological factors. Even though no study so far has
examined the effects of (chronic) stress on hemoglobin levels in
human populations, other psychological factors such as depressed
mood and diminished quality of life were associated with anemia
and decreased hemoglobin level in COPD patients [15] and in
community-dwelling elderly populations [16,17]. Decreased
hemoglobin levels and increased anemia were also observed in
cancer patients who have difficulties in understanding and
expressing their emotions (alexithymia) [18]. Conversely, treat-
ment with erythropoietin analogues may improve quality of life
and reduce depressive symptoms in anemic HF [19] and cancer
[20,21] patients.
Several forms of emotional distress such as depression, anxiety,
and distressed or Type D personality, have been related to the
above-mentioned pathophysiological mechanisms of anemia. Both
Type D personality (i.e. the combination of negative affectivity and
social inhibition [22]) and depression have been related to
heightened pro-inflammatory activity [23,24] in patients with
chronic HF. Inflammation is known to adversely affect the
hematopoietic system and hemoglobin balance [9]. Deregulation
of HPA axis activity is another mechanism by which hemoglobin
levels could be affected. Chronic cortisol exposure may suppress
erythropoiesis [25], potentially by the down-regulation of eryth-
ropoietin mRNA expression in the kidneys [26], and may promote
iron deficiency [27], thereby increasing the risk of anemia. Both
depression [28] and Type D personality [29,30] have been
associated with hyperactivity of the HPA axis, resulting in a higher
cortisol output. These studies showed that Type D personality was
independently associated with a larger cortisol awakening response
in patients hospitalized for acute coronary syndrome (ACS) [30]
and with a larger daytime cortisol output in ACS outpatients, four
months after their hospitalization for ACS [29], while adjusting for
important covariates and depression levels. Moreover, in HF
patients, larger cortisol/DHEA ratios have been related to lower
hemoglobin levels [31], suggesting that glucocorticoid imbalance
may also be involved in stress-related anemia in HF patients.
To date, the pathophysiological mechanisms through which
emotional distress could affect prognosis in patients with HF are
largely unknown. Since anemia negatively affects HF prognosis,
the current study prospectively examined the association of Type
D personality and affective symptoms with hemoglobin levels and
renal function in HF patients.
Methods
Ethics Statement
The study protocol was approved by the Medical Ethics
Committees of both hospitals and was conducted in accordance
with the most recent Helsinki Declaration (2008). All patients
provided written informed consent.
Participants and Procedure
The total sample comprised 313 consecutive HF outpatients
(response rate = 77%) recruited between October 2003 and June
2007 from the St. Elisabeth Hospital and the TweeSteden
Hospital, both of which are teaching hospitals in Tilburg, the
Netherlands.
Inclusion criteria consisted of left ventricular ejection fraction
(LVEF) #40%; age #80; NYHA class I-III; no hospital
admissions in the month prior to inclusion, and being stable on
oral medication for one month prior to inclusion. Patients were
excluded if they exhibited other life-threatening comorbidities
(e.g., cancer); evident cognitive impairments; psychiatric comor-
bidity (except for mood disorders); a poor command of the Dutch
language, or signs of acute infection at the time of blood sampling.
The mean age of the total sample was 65.969.9 years, and 74.8%
of these patients were male.
With regard to participation, patients were approached by their
attending cardiologist or specialized heart failure nurse. At
inclusion, patients were asked to fill out a questionnaire at home
to assess socio-demographic variables, Type D personality and
affective symptomatology. Questionnaires were returned in a
stamped, self-addressed envelope. All questionnaires were checked
for completeness. Any participants who had submitted incomplete
questionnaires were contacted by phone or mail, and asked for
details of the missing items. Any patients who failed to return the
questionnaire within two weeks received a reminder phone call or
a letter. Blood samples were collected to determine creatinine and
hemoglobin levels at inclusion and at 12-month follow-up.
Measures
Socio-demographics and clinical variables. Gender, age,
educational level, and marital status were assessed by means of
specially-designed questions in the survey. Clinical variables were
obtained from the patients’ medical records. These comprised
smoking status, body mass index (BMI), LVEF, NYHA, HF
etiology, time since diagnosis, cardiac history (previous myocardial
infarction, coronary artery bypass grafting or percutaneous
coronary intervention), device therapy (implantation of an
implantable cardioverter defibrillator, biventricular pacemaker or
pacemaker), and comorbidities (history of stroke or transient
ischemic attack, chronic obstructive pulmonary disease (COPD),
diabetes, hypercholesterolemia, hypertension, peripheral arterial
disease, and gastro-intestinal diseases). Finally, information on
prescribed medications (diuretics, spironolactone, ACE inhibitors,
angiotensin-II receptor blockers, beta blockers, calcium antago-
nists, aspirin, and statins) was recorded.
Anemia. K-DOQI guidelines (31) indicate a preference for
hemoglobin over hematocrit for the determination of anemia.
Therefore, plasma hemoglobin was determined using the Siemens
ADVIA 120 Hematology system in the hospitals’ central Clinical
Chemistry & Hematology Laboratory. World Health Organiza-
tion (WHO) guidelines indicate that hemoglobin levels of #12 g/
dL (7.5 mmol/L) for women and ,13 g/dL (8.1 mmol/L) for
men are indicative of anemia. However, the results of a recent
meta-analysis revealed that heterogeneity in reported prevalence
across the studies in question primarily resulted from variations in
the definition of anemia [5] used. Since there is no clear and
standardized definition of anemia in HF patients, we used
hemoglobin levels for the main regression analyses. For the
analysis on anemia, the WHO diagnostic rules for anemia were
used [32].
Renal dysfunction. Creatinine levels were determined by the
Siemens ADVIA 1650 Clinical chemistry system and were used to
evaluate the extent of kidney dysfunction. The MDRD equation
Type D and Hemoglobin in HF
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was used to calculate the glomerular filtration rate of creatinine
(GFRcreat) [33]. Following the K-DOQI-guidelines, renal dysfunc-
tion was defined as a GFRcreat of ,60 mL/min per 1.73 m
2 [34].
Affective symptoms. The Symptoms of Mixed Anxiety-
Depression index (SAD4) [35] was used to determine mixed
anxiety-depression symptomatology involving two anxiety items
(tension, restlessness) and two depression items (feeling blue,
hopelessness). Items are answered using a 5-point Likert scale,
ranging from 0 (‘not at all’) to 4 (‘very much’). The SAD4 showed a
high degree of correlation with the STAI anxiety scale (r = .69) and
the BDI depression scale (r = .71) in a sample of myocardial
infarction patients [35]. In patients with myocardial infarction a
high score on the SAD4 ($3 (upper tertile)) was associated with a
substantially increased risk of depressive disorder and/or anxiety
disorder [35]. The SAD4 has also been used as a predictor of
mortality in HF [36], as well as a screening tool for mixed anxiety-
depression symptoms in healthy populations [37] and in pregnant
women [38]. In the current sample, Cronbach’s alpha for this 4-
item scale was .89 and the 1-year test-retest correlation was .75.
Type D personality. The 14-item Type D scale (DS14) was
used to assess Type D personality [22]. Type D personality is
defined as the combination of the negative affectivity and social
inhibition personality traits. Individuals with a Type D personality
tend to experience negative emotions across time and situations,
and have the tendency not to express themselves in social
interaction, because of fear of rejection or disapproval by others.
The DS14 consists of two 7-item subscales, Negative Affectivity
and Social Inhibition that are internally consistent (Cronbach’s
a= .88/.86) and independent of health status [22]. Items are
answered using a 5-point Likert scale, ranging from 0 (‘false’) to 4
(‘true’). The standardized cut-off score $10 on both subscales was
used to classify individuals with a Type D personality [22]. Type D
personality has shown to be stable over an 18-month period and is
not confounded by indicators of disease severity such as LVEF
[39,40] or BNP [41].
Statistical Analyses
Discrete variables were compared with Chi-square tests and a
Fischer’s exact test, when appropriate. Student’s t-tests for
independent samples were used to compare continuous variables
at inclusion. Educational level (primary vs. secondary or higher),
marital status (single vs. having a partner), and NYHA class (I/II
vs. III) were dichotomized. Hemoglobin levels and creatinine were
checked for outliers (M63SD), which were excluded from further
analyses (2 values were omitted for hemoglobin at the 12-month
follow-up assessment while 5 values were omitted for creatinine
both at inclusion and 12-month follow-up). Skewness was
acceptable for both markers, and transformations were not
required. At inclusion, blood data were available for 254 patients
(due to missing data for hemoglobin (n = 54) and creatinine
(n = 26); 16 patients had no values for either). The prospective
regression analyses were based on 264 patients, due to missing
information on Type D status or affective symptomatology (n = 6)
or hemoglobin levels (including outliers) at 12-month follow-up
(n = 49).
A Student’s t-test was used to assess differences in hemoglobin
levels associated with Type D at inclusion. Chi-square tests were
used to examine the association between Type D, significant
affective symptomatology and anemia at inclusion and follow-up.
Logistic regression including a set of clinical variables was used
predict changes in anemia status during follow-up.
To investigate Type D personality and affective symptomatol-
ogy as independent associates of hemoglobin levels at 12-month
follow-up, two multivariable regression models were tested (after
testing both independent variables in separate unadjusted models).
These models included other known contributors to anemia risk as
statistical covariates, such as kidney dysfunction (GFRcreat,
diuretics use), NYHA class, RAAS medication (ACE inhibitor or
angiotensin receptor blocker), BMI and gender. Finally, the
affective symptomatology score was added, to determine whether
the personality effect was independent of mood. This final step was
repeated for the dichotomized variable, indicating significant
affective symptomatology (SAD4.3). A Sobel mediation test was
used to assess whether covariates that significantly reduced the
relation between Type D or affective symptomatology and future
hemoglobin were mediators of the relationship. Controls for
baseline hemoglobin levels were omitted, since this would
overcorrect the regression model and introduce multicollinearity,
due to the high degree of correlation with hemoglobin levels at
follow-up (dependent variable). Statistical analyses were performed
using PASW 19 for Windows (IBM SPSS Inc. Chicago, Illinois,




The prevalence of Type D personality was 21% and significant
affective symptomatology was present in 34% of the patients. On
average, 7.264.5 years had passed since the patients were first
diagnosed with heart failure. The Type D patients did not differ
significantly from non-Type D patients in terms of demographics,
biomedical risk factors, disease characteristics, cardiovascular
interventions, or prescribed medications at inclusion. Sample
characteristics stratified by Type D personality are presented in
Table 1.
In addition, there were no significant differences in the
prevalence of cerebrovascular accidents (overall prevalence 9%;
p = .21), transient ischemic attacks (overall prevalence 9%; p = .39),
peripheral arterial disease (overall prevalence 16%; p = .94),
COPD (overall prevalence 14%; p = .96), liver disease (overall
prevalence 4%; p = .93) or gastrointestinal disease (overall preva-
lence 7%; p = .06, with 13% vs. 6% more prevalent in Type Ds).
Hemoglobin and Anemia Prevalence
Hemoglobin levels at inclusion were similar for non-Type D
and Type D HF patients (t = 1.2, p = .23) as well as for patients
with and without significant affective symptomatology (t = 1.8,
p = .08). At 12-month follow-up, hemoglobin levels significantly
differed as a function of Type D personality (t = 2.28, p = .02;
Figure 1a), but differed only marginally as a function of affective
symptomatology (t = 1.9, p = .06). Levels of affective symptom-
atology were modestly negatively correlated with hemoglobin
levels both at baseline (r = –.14, p = .02) and 12-month follow-up
(r = –.11, p = .08). According to WHO criteria, the prevalence of
anemia at inclusion was 16% in both non-Type D and Type D
patients. However, at 12 months, 17% of non-Type Ds and 29%
of Type D patients were classified as anemic (See Figure 1b;
x2 = 3.51, p = .06). Regarding clinical predictors of change in
anemia status over the one-year period, logistic regression analysis
showed that female gender, presence of renal dysfunction at
baseline in the absence of anemia, deterioration of renal function,
NYHA functional class III, and a longer HF history were
predictive of developing anemia (Table 2). Higher baseline
hemoglobin levels were protective for becoming anemic.
Type D and Hemoglobin in HF
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(n = 64) non-Type D (n = 249) p
Demographics
Male gender 75.3 (235) 71.9 (46) 76.2 (189) .47
Age (yrs), mean (SD) 65.9 (9.9) 67.2 (10.4) 65.5 (9.8) .25
Living without a partner 25.6 (80) 29.7 (19) 24.6 (61) .41
Affective symptoms
SAD4 score, mean (SD) 2.4 (3.1) 5.4 (3.9) 1.6 (2.3) ,.0005
SAD4$3 33.6 (185) 78.1 (50) 22.0 (54) ,.0005
Biomedical risk factors
BMI (kg/m2) b 27.9 (5.0) 28.0 (5.5) 27.9 (4.9) .89
Smoking 22.8 (71) 15.6 (10) 24.6 (61) .13
Hypertension 35.6 (111) 37.5 (24) 35.1 (87) .72
Hypercholesterolemia 54.8 (171) 57.8 (37) 54.0 (134) .59
Diabetes 23.7 (74) 26.6 (17) 23.0 (57) .55
Disease characteristics
Ischemic etiology b 58.1 (180) 53.2 (33) 59.3 (147) .39
LVEF, mean (SD) 31.7 (6.7) 32.2 (6.3) 31.6 (6.8) .53
NYHA class III c 31.7 (99) 35.9 (23) 30.6 (76) .42
Time since diagnosis (yrs), mean (SD)b 7.2 (4.5) 7.7 (5.2) 7.0 (4.2) .23
Interventions
PCI 16.0 (50) 15.6 (10) 16.1 (40) .92
CABG 26.9 (84) 29.7 (19) 26.2 (65) .58
Device therapy d 12.5 (39) 12.5 (8) 12.5 (31) .99
Prescribed medications
Diureticse
Lisdiuretics only 62.2 (194) 76.6 (49) 58.5 (145)
Thiazides only 3.2 (10) 1.6 (1) 3.6 (9) .06
Combined 6.1 (19) 4.7 (3) 6.5 (16)
Beta blockers 66.5 (206) 68.3 (43) 66.0 (163) .73
ACE inhibitors 71.8 (224) 75.0 (48) 71.0 (176) .52
ARB 19.9 (62) 21.9 (14) 19.4 (48) .65
Digoxin 25.3 (79) 32.8 (21) 23.4 (58) .12
Calcium antagonists 13.5 (42) 25.0 (16) 10.5 (26) .002
Oral anticoagulants 47.4 (148) 40.6 (26) 49.2 (122) .22
Aspirin 38.1 (93) 40.6 (26) 37.5 (93) .65
Statins 53.5 (167) 53.1 (34) 53.6 (133) .94
Psychotropic medication 13.8 (43) 18.8 (12) 12.5 (31) .20
Renal function
Renal dysfunction at baseline f 30.4 (95) 31.3 (20) 30.1 (75) .86
GFRcreat at baseline mean (SD) 69.8 (20.3) 69.9 (19.8) 69.8 (23.4) .98
Change in GFRcreat during follow-up mean (SD) 21.6 (15.1) 28.2 (19.7) 20.1 (13.6) .02
aResults are presented as % (n), unless stated otherwise.
bDue to missing data for 2–23 patients, analyses were conducted using the available data.
cNYHA class III versus NYHA class I-II.
dEither a single, biventricular pacemaker or an implantable cardioverter device.
e28.1% of patients were not prescribed diuretics. Some patients were prescribed a combination of potassium-sparing diuretics and lisdiuretics (n = 12, 3.6%).
fGFRcreat,60 mL/min per 1.73 m
2.
ARB = angiotensin-II receptor blockers; BMI = body mass index; CABG = coronary artery bypass grafting; LVEF = left ventricular ejection fraction; NYHA = New York Heart
Association functional class; PCI = percutaneous coronary intervention; GFRcreat = glomerular filtration rate of creatinine.
doi:10.1371/journal.pone.0058370.t001
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Type D Personality, Affective Symptoms and Hemoglobin
at 12-month Follow-up
In univariate analysis, Type D personality was significantly
associated with future hemoglobin levels (b= –.18, p = .005).
Results of the covariate-adjusted analysis showed that Type D
personality remained an independent associate of decreased
hemoglobin levels at 12-month follow-up (b= –.16, p = .007). In
addition, renal dysfunction, gender, and NYHA class were
associated with hemoglobin levels at 12-month follow-up (see
Table 3 for details of the fully adjusted model, including affective
symptomatology). Collinearity statistics showed that tolerance was
well within the acceptable range, and that inter-correlation
between predictors was low (r = –.23 to.17). In total, 25% of
variance was accounted for by the variables in the model, which is
in keeping with a large total effect size (f2 = .36). The change in R2
when Type D personality was added to the model was.011,
adding.013 to the effect size, an effect equal in proportion to the
effect of NYHA class (which added 0.03 to the effect size).
In univariate analyses, a higher level of affective symptomatol-
ogy was prospectively associated with lower hemoglobin levels
(b= –.13, p = .04 and b= –.13, p = .045, for continuous and
dichotomized affective scores, respectively). However, in adjusted
analyses, this association was no longer significant (b= –.09,
p = .13 and b= –.09, p = .12, for continuous and dichotomized
scores), as gender and renal disease attenuated the link between
affective symptomatology and hemoglobin levels. Finally, adding
affective symptomatology to the fully adjusted Type D model did
not change the effect of Type D personality on future hemoglobin
levels (Table 3).
Type D Personality and Deterioration of Renal Function
Type D was also associated with a larger deterioration in renal
function as indicated by a greater change in GFRcreat over the
follow-up period in Type D patients as compared to non-Type Ds,
p = .02 (Table 1). Based on the logistic regression model of clinical
predictors of change in anemia status (Table 2), deterioration of
renal function was seen as a potential explanatory mechanism, one
that could mediate the relation between Type D and future levels
of hemoglobin. We employed the Sobel test for mediation analysis,
which showed that change in GFRcreat was a predictor of lower
hemoglobin levels at follow-up (b= –.22, p = .001). It also
Figure 1. a-b Hemoglobin (1a) and anemia (1b) at inclusion and
follow-up by Type D personality. Levels of hemoglobin and
prevalence of anemia at inclusion and follow-up by Type D personality.
Figure 1A: Hemoglobin levels at inclusion and 12 months follow-up
(FU) stratified by Type D personality; Grey line = non-Type D patients,
black line = Type D patients; the error bars represent 1 standard error of
the mean. Figure 1B: Percentage of patients with an anemia diagnosis
according to WHO guidelines ( = anemia cases), stratified by Type D
personality; Grey bars = non-Type D patients, black bar = Type D
patients. ** = p,.05 * = p,.10, ns = non-significant.
doi:10.1371/journal.pone.0058370.g001
Table 2. Clinical predictors of change in anemia status over
1-year follow-up.
B SE Wald P value OR 95% CI
Time since diagnosis 0.2 0.06 6.77 .009 1.17 1.04–1.32
Hemoglobin at inclusion 23.1 0.7 20.19 ,.001 0.05 0.01–0.18
BMI 0.1 0.02 0.27 .60 1.01 0.97–1.06
Change in GFRcreat 0.1 0.03 11.22 .001 1.09 1.04–1.15
Renal dysfunction at inclusion 1.9 0.7 8.58 .003 6.90 1.90–25.15
NYHA class III 0.1 0.7 0.02 .89 1.11 0.28–4.38
Female gender 2.9 0.9 10.08 .001 17.9 3.0–106.4
BMI = body mass index; GFRcreat = glomerular filtration rate of creatinine; NYHA
class = New York Heart Association functional class.
doi:10.1371/journal.pone.0058370.t002
Table 3. Independent associates of hemoglobin levels at 12-
month follow-up.
Standardized b t p
Type D personality 2.15 22.29 .02
Female gender 2.29 24.96 ,.001
Renal dysfunction at inclusion 2.28 24.93 ,.001
NYHA class 2.12 21.97 .05
RAAS medication 2.03 20.45 .66
BMI .04 0.76 .45
Time since diagnosis 2.12 22.04 .04
Affective symptomatology 2.01 20.10 .92
NYHA: New York Heart Association; BMI: body mass index; RAAS: renin-
angiotensin-aldosterone system.
doi:10.1371/journal.pone.0058370.t003
Type D and Hemoglobin in HF
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e58370
explained the association between Type D and future lower
hemoglobin levels (Type D effect in this model: b= –.05, p = .47).
Discussion
Type D personality was prevalent in 21% of the current patient
sample, and significant affective symptomatology was present in
34% of the patients. Type D personality was associated with lower
hemoglobin levels at 12-months follow-up, independent of baseline
renal dysfunction, gender, time since diagnosis, medication
affecting the renin-angiotensin system, body mass index and
NYHA functional class. Affective symptomatology was related to
future hemoglobin levels in univariate analyses but not in adjusted
analysis. Moreover, adding affective symptomatology to the
regression model had no impact on the effect of Type D
personality. Importantly, Type D personality was also associated
with deterioration of renal function over the year of follow-up, and
a Sobel mediation test showed that deterioration of renal function
explained the association between Type D and future hemoglobin
levels.
The present findings are in line with studies in patients with
cancer [18,20,21], or COPD [15], and in community-dwelling
elderly populations [16,17], which have shown that increased
psychological stress, depressed mood and diminished quality of life
were associated with anemia or decreased hemoglobin levels. The
current results also build on previous findings in rodents relating
psychological stress to plasma iron deficiency and diminished
erythropoiesis [13], and on a clinical study which showed that the
erythropoietin analogue Darbepoetin-a had a beneficial effect on
depressive symptoms in HF patients [19]. Interestingly, the
treatment of anemia has been associated with an improvement
in quality of life and a depressed mood [21].
Inflammatory activation is one of the mechanisms by which
Type D personality might affect hemoglobin levels and renal
function. HF patients with Type D personality are characterized
by increased levels of pro-inflammatory cytokines [23,42], as is
depression [24,43]. The pro-inflammatory state is an essential
component of anemia or chronic disease [44], as TNF-a and IL-6
inhibit erythropoietin production in the kidney [45] and the
proliferation of bone marrow erythroid progenitor cells [46].
Increased levels of pro-inflammatory cytokines have also been
associated with poor renal function [47] and a further decline in
renal function over time [48]. Future studies are needed to
determine whether inflammation could be an explanatory
mechanism for the association between psychological distress
and lower hemoglobin levels.
Both depression and Type D personality have been associated
with deregulated HPA axis activity, resulting in higher daytime
cortisol levels [28,29]. Chronically elevated cortisol may directly
suppress erythropoiesis [25], potentially by suppressing the
expression of erythropoietin mRNA in the kidneys [26], and
could also affect iron metabolism [27], resulting in lower
hemoglobin levels [31]. Cortisol could indirectly affect hemoglobin
levels by promoting a pro-inflammatory state, as chronically
elevated cortisol levels boost the secretion of pro-inflammatory
cytokines [49]. Future studies should determine whether cortisol
explains the association between Type D personality and
hemoglobin.
Behavioral mechanisms that might affect hemoglobin levels
include poor self-care and poor medication adherence. Non-
compliance with guidelines regarding fluid intake or with diuretic
treatment may induce hemodilution, thereby cutting hemoglobin
levels. Type D personality has been related to poor medication
adherence in patients with acute coronary syndrome [50], but not
with poor self-management of health behaviors in heart failure
patients [51]. In the current study, Type D was not associated with
any changes in the prescription of diuretics or RAAS medication
over the follow-up period. However, we have no information on
the actual medication taken by these patients.
The present study underscores the clinical relevance of anemia
in HF and suggests that psychological distress may be an
important factor. Given that anemia in HF is associated with
increased mortality, while the correction of anemia might prevent
an impaired outcome [52], the close monitoring and targeting of
hemoglobin levels might be a promising avenue for efforts to
improve clinical outcomes. HF patients with a Type D personality
are twice as likely as their non-Type D counterparts to fail to
consult a physician in connection with their HF symptoms [51].
Moreover, progressive renal dysfunction largely explained the
relation between Type D and a decrease in hemoglobin levels.
Therefore, close monitoring of HF and renal symptoms seem to be
particularly important in Type D patients. Further research is
needed to determine whether targeting hemoglobin in emotionally
distressed patients could improve their chances of survival. Some
trials (CREATE, CHOIR) have reported that, in the presence of
renal failure, increasing the level of hemoglobin may have several
deleterious side-effects, such as vasoconstriction and venous
thrombosis. These findings could challenge the benefits of anemia
correction in HF [53,54]. It is difficult to extrapolate these results
to HF patients as these trials focused primarily on renal failure,
and only a subsample of participants was diagnosed with HF [55].
A recent meta-analysis of ESP treatment for anemia in HF
concluded that such treatment did not induce these side effects
(hypertension, venous thrombosis) or adverse events. On average,
however, renal function in these studies was better than in the
CREATE and CHOIR trials [55]. As a decline in renal function
was a key characteristic of Type D patients with HF, this needs to
be carefully investigated in future research. Improving iron
deficiency in anemic HF patients (FAIR-HF) enhanced their
quality of life while alleviating depressed and anxious moods.
However, these benefits were unrelated to the change in anemia
[56]. This is in keeping with the current findings for affective
symptomatology, which has been shown to be unrelated to
anemia, when controlling for disease severity, renal dysfunction
and angiotensin-related medication.
A previous study in cancer patients showed that depressed mood
and poor quality of life impinged on the effectiveness of
erythropoietin-a therapy for anemia. The present study also
supports previous recommendations on screening for psycholog-
ical factors, in order to obtain a fuller understanding of the
complex clinical picture of HF [57]. The identification of patients
with a Type D personality might benefit the clinical care of HF, as
Type D patients are at increased risk of lower hemoglobin levels,
and the treatment of anemia may be beneficial in HF.
The results of the current study should be interpreted with
appropriate caution, due to several limitations. HF patients are
characterized by multi-morbidity and polypharmacy. In the
present study, this seems to be slightly more pronounced for some
biomedical variables in Type D patients, although not significantly
so. It may be that these variables have small, cumulative effects on
disease severity and anemia. However, after adjustment for disease
severity and renal dysfunction, Type D personality showed an
independent association with future hemoglobin. This supports the
hypothesis that the effect of psychological stress is of significant
added value. No information was available on the dosage of
prescribed medications, or on iron blood levels or iron intake.
Further, affective symptomatology was assessed by a 4-item
screening instrument for mixed anxiety-depression symptoms
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and not by more standard scales or psychiatric interviews. Since
the SAD4 asks to report affective symptomatology over the past
week, it provides no information on the duration of the reported
symptoms. This may imply that the results do not necessarily
generalize to depression or anxiety diagnosis. Although the current
study design was longitudinal, the lack of a control group means
that no final conclusions can be drawn regarding causality.
Baseline hemoglobin was not included, due to the potential
multicollinearity with follow-up levels of hemoglobin. Finally, no
information was available on the activity of the sympathetic
nervous system, or the HPA axis, precluding any final conclusions
on the pathophysiological mechanisms of effect.
Future research should examine the stress-related mechanisms
through which hemoglobin levels are affected in HF patients with
Type D personality. Does altered HPA axis function or
sympathetic activity explain differences in hemoglobin levels
between Type D vs. non-Type D individuals? A prospective,
observational cohort study in patients with HF in which basal
daytime levels of cortisol, norepinephrine and hemoglobin are
collected at multiple measurement occasions would help to resolve
the current paucity of knowledge on pathophysiological mecha-
nisms. In addition, further research is needed to determine
whether treatment with erythropoiesis-stimulating proteins could
improve hemoglobin levels in HF patients with a Type D
personality. This could initially be explored in an experimental
setting in which erythropoiesis-stimulating proteins are given to
Type D and non-Type D anemic individuals without heart
disease, before extending the study towards anemic cardiac
patients.
In conclusion, Type D personality was associated with lower
hemoglobin levels at 12-month follow-up, independent of renal
dysfunction, gender, NYHA class, BMI, RAAS medication and
affective symptomatology. Type D personality was also associated
with deterioration of renal function over the follow-up period,
which could explain the decrease in hemoglobin levels observed in
Type D patients. Identifying psychological risk factors and their
mechanisms of action might enhance our understanding of the
complex disease processes involved in HF.
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